Helicobacter Pylori Infection Clinical Trial
Official title:
Oral H. Pylori Prevalence in Intellectually & Developmentally Disabled Adults
The purpose of this study is to determine if the bacteria that cause gastric infections can be found in the mouths of intellectually and developmentally disabled persons. If the bacteria that causes gastric infections is found in the mouth it may be swallowed and contribute to gastric infections.
Helicobacter pylori (H. pylori) bacteria play a significant role in the etiology of gastric
and duodenal ulcers, gastro-esophageal reflux disease and gastric adenocarcinoma.
Intellectually disabled/developmentally disabled (ID/DD) adults are reported to have H.
pylori infection at approximately twice the rate of the general population and experience
recurrence at a seven-fold higher rate, contributing to increased mortality due to gastric
cancer. The oral cavity may serve as a reservoir for H. pylori and subsequently contribute
to the recurrence of gastric infection.
Numerous studies have identified H. pylori in dental plaque, an environment that is
relatively resistant to systemic antibiotics. Systemic antibiotics are used to treat H.
pylori infections but do not appear to eradicate H. pylori in the mouth. The oral status of
ID/DD adults is reported to be poor due to inadequate oral hygiene, leading to increased
plaque, caries and periodontal disease. Furthermore, poor oral status (periodontal disease)
has been associated with H. pylori seropositivity. While ID/DD adults have elevated rates of
H. pylori gastric infections, nothing is known about the prevalence of H. pylori in their
oral cavities.
The proposed exploratory research will address the following questions in this disadvantaged
population: 1) What is the prevalence of H. pylori in the dental plaque in ID/DD adults?, 2)
Is poor oral status associated with H. pylori gastric infection?, and 3) Does H. pylori
persist in the dental plaque of ID/DD adults after systemic antibiotic treatment, and if so,
is it associated with recurrence of gastric infection? This epidemiological study of 112
institutionalized ID/DD and 112 control subjects will involve oral examinations, indices,
dental plaque sampling, and C13 Urea Breath Tests at baseline to determine prevalence.
Nested Polymerase Chain Reaction (PCR) analyses will be used to detect H. pylori in the
dental plaque. For those ID/DD subjects who have a positive gastric H. pylori test at
baseline, repeated oral sampling and gastric tests will be performed over 1 year to
determine persistence.
If poor oral health status and oral H. pylori prevalence are correlated with gastric H.
pylori infections, a future pilot clinical trial will be conducted to investigate the
concordance between genetic strains of H. pylori in the mouth and stomach, the effect of
various interventions on oral health, oral H. pylori prevalence, and H. pylori gastric
infections in ID/DD adults. The proposed research responds to the Surgeon General's National
Call to Action to conduct studies to elucidate underlying mechanisms and determine any
causal associations between oral infections and systemic conditions. The proposed research
also addresses the need to reduce health disparities, improve quality of life, and reduce
morbidity and mortality in vulnerable populations.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05061732 -
Helicobacter Pylori Eradication and Follow-up
|
Phase 4 | |
Completed |
NCT03779074 -
Comparing the Efficacy of Hybrid, High-dose Dual and Bismuth Quadruple Therapies
|
Phase 3 | |
Completed |
NCT06076681 -
A Study to Evaluate Preliminary Helicobacter Pylori Eradication After Multiple Doses of TNP-2198 Capsules Combined With Rabeprazole Sodium Enteric-coated Tablets, or Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules
|
Phase 1/Phase 2 | |
Recruiting |
NCT05329636 -
Auto Fecal Microbial Transplant Post Helicobacter Pylori Antibiotic Therapy
|
Phase 1/Phase 2 | |
Recruiting |
NCT05065138 -
Comparison of Helicobacter Pylori Eradication Effect Before and After Training of Gastroenterologists
|
N/A | |
Completed |
NCT05049902 -
Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication
|
Phase 4 | |
Not yet recruiting |
NCT06200779 -
Tailored vs. Empirical Helicobacter Pylori Infection Treatment
|
Phase 4 | |
Not yet recruiting |
NCT06037122 -
Efficacy of Low-dose Vonoprazan for Helicobacter Pylori Eradication
|
||
Completed |
NCT04617613 -
Comparing Different Regimens for Eradication of Helicobacter Pylori in Kuwait
|
Phase 4 | |
Withdrawn |
NCT02552641 -
Food Effect on the Eradication Rate of H. Pylori With Triple Therapy With Esomeprazole
|
Phase 4 | |
Completed |
NCT02873247 -
Standardize Communication With General Practitioner & Patient for Improved Eradication of Helicobacter Pylori
|
||
Completed |
NCT02557932 -
Comparison of 7-day PPI-based Standard Triple Therapy and 10-day Bismuth Quadruple Therapy for H. Pylori Eradication
|
Phase 3 | |
Recruiting |
NCT02249546 -
Efficacy of Acetylcysteine-containing Triple Therapy in the First Line of Helicobacter Pylori Infection
|
Phase 4 | |
Completed |
NCT01933659 -
Anti-H. Pylori Effect of Deep See Water
|
Phase 3 | |
Unknown status |
NCT01464060 -
14-day Quadruple Hybrid vs. Concomitant Therapies for Helicobacter Pylori Eradication
|
Phase 4 | |
Recruiting |
NCT05549115 -
Susceptibility-Guided Sequential Therapy for Helicobacter Pylori Infection
|
N/A | |
Recruiting |
NCT05728424 -
One vs Two Weeks Treatment for H.Pylori Eradication A RANDOMIZED NON-INFERIORITY PLACEBO CONTROLLED TRIAL
|
Phase 3 | |
Recruiting |
NCT05997433 -
Efficacy of 7-day Versus 14-day Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori(SHARE2302)
|
N/A | |
Completed |
NCT04708405 -
The Relationship Between Helicobacter Pylori Infection and Inflammatory Bowel Diseases: A Real-life Observation
|
||
Completed |
NCT06282484 -
A Study on the Relationship Between Gastric Xanthoma and Gastric Cancer and Precancerous Lesions
|